Effect of endostar combined elemene on patients with advanced liver cancer
Wei Zhu,Hengjun Shi,Jingyong Ding,Qinyou Ren,Jun Liang,Jin Zheng,Jiangang Yang,Ke Wang,Hui Zhang,Xiaojuan Zhang,Hui Li
DOI: https://doi.org/10.3969/j.issn.1672-4992.2014.08.39
2014-01-01
Journal of Modern Oncology
Abstract:To study the effect of recombinant endostatin injection and the blood circulation antineoplas-tic agents(elemene)on patients with advanced liver cancer. Methods:All 36 cases with advanced hepatocellular car-cinoma were randomly divided into treatment group contain 16 and control group 20 patients. The treatment group was treated by the human endostatin and elemene. The control group by cinobufacini injection. Results:Survival rate of six months in treatment group was 25. 00% ,rate for a year was 18. 75% ,median survival time for seven months was fif-teen days. In control group 20. 00% survival rate for six months,0 survival rate for a year and the median survival time for four months was five days. Compared the survival curves of these two groups,the results have statistically difference(P ﹤ 0. 01). According to the QOL in - LC V2. 0 to assess the quality of life,the treatment group's physical function,pymptom,side effect and score of total scale were higher than the control group(P ﹤ 0. 05),and compared with the control group,no significant difference(P ﹥ 0. 05)in the aspects of mental function and social function. In the function of blood,liver and kidney,and alpha - fetoprotein measurement and other laboratory tests,both treatment group and control group had no difference before and after treatment(P ﹥ 0. 05). Use the survival time as the depend-ent variable,age( ﹥ 50 years and ≤50 years),cirrhosis(decompensated and compensated),hepatitis B history(and without),AFP(≥400μg/ ml,﹤ 400μg/ ml)as prognostic factors and signment. After multivariate Cox regression a-nalysis,all P ﹥ 0. 05. These independent prognostic factors can not affect the survival time of patients with advanced hepatocellular carcinoma. Conclusion:Human endostatin and elemene can improve the survival rate and quality of life of patients with advanced hepatocellular carcinoma.